Ifinatamab deruxtecan
Ifinatamab deruxtecan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Prostate Cancer、Prostatic Neoplasms。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
14 项
全球在招研究
3 项
已进入 III/IV 期
35 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- Daiichi Sankyo
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Brazil、Chile、中国、Czechia、法国、德国、意大利、日本、挪威、Singapore、South Korea
正在招募患者的 Ifinatamab deruxtecan 研究
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06780111A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
I 期 / II 期招募中美国Argentina澳大利亚比利时NCT06330064A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
I 期 / II 期招募中美国法国日本西班牙NCT06362252A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
I 期 / II 期招募中美国BrazilChile中国NCT07405151KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
I 期 / II 期招募中美国加拿大HungaryIsraelNCT04165070A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
I 期 / II 期招募中美国ArgentinaChile中国NCT07227597A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
III 期招募中美国澳大利亚奥地利比利时NCT06203210A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
I 期 / II 期招募中美国Argentina澳大利亚ChileNCT06780137A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
II 期招募中美国Chile德国GreeceNCT06780085A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
III 期招募中美国比利时中国丹麦NCT06644781Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
II 期招募中美国Chile中国德国NCT06780098A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
I 期 / II 期招募中美国Argentina澳大利亚BrazilNCT06863272A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
III 期招募中美国Argentina澳大利亚奥地利NCT06925737A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
I 期 / II 期招募中美国澳大利亚比利时CzechiaNCT07630974
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。